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Recurrent rearrangements of chromosome 1q21.1 that occur via non-allelic homologous recombination have
been associated with variable phenotypes exhibiting incomplete penetrance, including congenital heart dis-
ease (CHD). However, the gene or geneswithin the∼1 Mb critical region responsible for each of the associated
phenotypes remainsunknown.Weexamined the 1q21.1 locus in 948patientswith tetralogy of Fallot (TOF), 1488
patients with other forms of CHD and 6760 ethnically matched controls using single nucleotide polymorphism
genotyping arrays (Illumina 660WandAffymetrix 6.0) andmultiplex ligation-dependent probe amplification.We
found that duplication of 1q21.1 was more common in cases of TOF than in controls [odds ratio (OR) 30.9, 95%
confidence interval (CI) 8.9–107.6); P 5 2.2 3 1027], but deletion was not. In contrast, deletion of 1q21.1 was
more common in cases of non-TOF CHD than in controls [OR 5.5 (95% CI 1.4–22.0); P 5 0.04] while duplication
was not. We also detected rare (n 5 3) 100–200 kb duplications within the critical region of 1q21.1 in cases of
TOF. These small duplications encompassed a single gene in common, GJA5, and were enriched in cases of
TOF in comparison to controls [OR 5 10.7 (95% CI 1.8–64.3), P 5 0.01]. These findings show that duplication
and deletion at chromosome 1q21.1 exhibit a degree of phenotypic specificity in CHD, and implicate GJA5 as
the gene responsible for the CHD phenotypes observed with copy number imbalances at this locus.
INTRODUCTION
Congenital heart disease (CHD) is the most common congeni-
tal anomaly, with an incidence of 7 per 1000 live births (1).
CHD may occur as part of recognized chromosomal and Men-
delian syndromes (2–4), but in 80% of cases it manifests as a
non-syndromic, non-Mendelian condition. Significant familial
recurrence risk has been demonstrated in such ‘sporadic’ CHD
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cases, indicating complex genetic contributions to the risk of
most CHD (5,6). The most common cyanotic form of CHD
is tetralogy of Fallot (TOF), which occurs in 1 in 2500
live births (1). TOF is characterized by a ventricular septal
defect, over-riding of the aortic valve due to anterocephalad
deviation of the outlet septum, right ventricular outflow tract
obstruction and right ventricular hypertrophy.
Recently, rearrangement hotspots in the human genome
which occur via non-allelic homologous recombination
(NAHR), and result in recurrent copy number imbalances,
have been identified (7,8). One such locus is situated at
1q21.1; copy number variants (CNVs) at this locus have been
associated with variable phenotypes exhibiting incomplete
penetrance (9–12), including both syndromic (9–11) and non-
syndromic (isolated) (11,13) forms of CHD. A recent study by
Greenway et al. (13) identified 1q21.1 copy number imbalances
in 5 out of 512 isolated TOF cases. Although these findings were
highly statistically significant when compared with controls
(P ¼ 0.0002), they as yet await replication for TOF. Moreover,
the gene or genes responsible for TOF risk at this locus remain
unidentified among the 11 RefSeq genes in the 1 Mb critical
region of 1q21.1. Of these genes, gap junction protein a-5
(GJA5, Connexin40, Cx40) has previously been proposed as
the candidate gene for several cardiac disease phenotypes, in-
cluding CHD (14–17). Both Gja5 heterozygous (18%) and
homozygous-null (33%) mice exhibit complex heart defects,
including conotruncal and endocardial cushion defects (14).
However, no GJA5 point mutation or GJA5-specific CNV has
been found in CHD patients to date (9,13). We thus examined
the 1q21.1 locus in a large cohort of isolated CHD patients
(n ¼ 2436) in order to estimate more precisely the contribution
of 1q21.1 rearrangements to CHD risk, and to identify the
causative gene for CHD at this locus.
RESULTS
CNV analyses and concordance between methods
of detection
We performed genome-wide CNV analysis on a total of 807 TOF
cases and 841 controls using a combination of the PennCNV (18)
and QuantiSNP (19) CNV-calling algorithms on data generated
using Illumina 660W-Quad chips and found one duplication
locus that reached statistical significance for enrichment in
TOF versus controls at 1q21.1 (7/807 versus 0/841; P ¼
0.007). A subset of the same TOF patients (n ¼ 198) was also
analyzed with the Birdseye algorithm on data generated using
Affymetrix 6.0 chips. Additionally, we performed targeted multi-
plex ligation-dependent probe amplification (MLPA) analysis on
the 1q21.1 locus in 570 TOF probands, 429 of which were also
typed on Illumina 660W, yielding a total of 948 TOF cases exam-
ined in this study. A total of 1488 non-TOF CHD cases with clin-
ical diagnoses as shown in Table 1 were analyzed using the
PennCNV and QuantiSNP algorithms on Illumina 660W-Quad
data; MLPA on the 1q21.1 locus was also performed on 428 of
these individuals. When data from the four methods of detection
in all cases were merged, we found 100% concordance in CNVs
detected in the 1q21.1 locus between the methods used in this
study. All CNVs that were detected from the Illumina 660W
arrays in individuals that had not also been analyzed with
another independent method (n ¼ 8) were successfully validated
with MLPA.
Frequency of 1q21.1 rearrangements in control
populations
We examined the frequency of NAHR-mediated 1q21.1 rear-
rangements in 841 individuals from a French population
cohort, 5919 WTCCC2 control individuals and 4150 control
individuals from previously published studies (8,20,21) that
used high-density single nucleotide polymorphism (SNP) plat-
forms comparable to those used in this study. Three duplica-
tions and four deletions in 10910 controls were observed
(see Supplementary Material, Table S1).
Microduplication of 1q21.1 is strongly associated
with sporadic, isolated TOF
We identified NAHR-mediated duplications of 1q21.1 that
span the previously reported critical region (9,10) in eight un-
related TOF probands (Fig. 1 and Table 2). The duplications
were found to be de novo in one proband, inherited from an
unaffected mother in three probands and of unknown inherit-
ance (due to unavailability of parental samples) in the remain-
ing four probands. There were no occurrences of 1q21.1
deletion in our TOF cohort. Thus, our findings showed that
1q21.1 microduplications are strongly associated with TOF
[8/948 versus 3/10910; P ¼ 2.2 × 1027; odds ratio (OR) ¼
30.9, 95% confidence interval (CI) ¼ 8.9–107.6; Table 3],
with population attributable risk (PAR) ¼ 0.92%. In contrast,
Table 1. Non-TOF CHD phenotype distribution
Cardiac malformation n
Ventricular septal defect 162
Atrial septal defect 290
Atrioventricular septal defect 63
Transposition of the great arteries 173
Congenitally corrected transposition of the great arteries 37
Common arterial trunk 24
Double-outlet left ventricle 1
PA with ventricular septal defect 18
Double-outlet right ventricle 18
Pulmonary stenosis 79
PA with intact ventricular septum 18
Aortic valve abnormalities 131
Hypoplastic left heart syndrome 15
Mitral valve abnormalities 23
Double inlet left ventricle or right ventricle 23
Ebstein malformation 14
Tricuspid valve abnormalities 32
Aortic arch abnormalities 161
Patent ductus arteriosus 66
Partial anomalous pulmonary venous drainage 19
Total anomalous pulmonary venous drainage 9
Left isomerism 12
Right isomerism 11
Univentricular heart 14
Situs inversus/dextrocardia 5
Heterotaxy 8
Coronary artery anomaly 3
Other 59
Total 1488
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we found no evidence that microdeletions of 1q21.1 are asso-
ciated with TOF (0/948 versus 4/10910; Table 3). Additional
phenotypic details of all probands with 1q21.1 CNVs are
presented in Supplementary Material, Table S2.
GJA5 duplication is associated with TOF
In addition to NAHR-mediated events, we found 100–200 kb
rare duplications within the critical region of 1q21.1 in three
patients with TOF. All of these duplications encompass
GJA5, a strong candidate gene for CHD (14–17). We did
not find any deletion within the critical region of 1q21.1 in
our TOF cohort. This smaller duplication variant occurred in
2/6760 controls. Thus, small duplications encompassing the
GJA5 gene were also enriched in our TOF cohort compared
with controls (P ¼ 0.01; OR ¼ 10.7, 95% CI ¼ 1.8–64.3).
Additionally, we found a GJA5 triplication in one patient
with pulmonary atresia (PA), like TOF, a cardiac outflow
tract phenotype, in the non-TOF CHD cohort (Fig. 2).
Microdeletion of 1q21.1 is associated with isolated
congenital heart defects
Examination of the 1q21.1 locus in 1488 cases with other forms
of isolated CHD (mixed, non-TOF) revealed three NAHR-
mediated deletions and no duplications that spanned the entire
critical region (Fig. 1 and Table 2). Thus, 1q21.1 deletion was
associated with isolated non-TOF CHD (3/1488 versus
4/10910; P ¼ 0.04; OR ¼ 5.5, 95% CI ¼ 1.4–23.2 with
PAR ¼ 0.17%, Table 3). In contrast, we found no evidence of
association between 1q21.1 duplication and non-TOF CHD
(0/1488 versus 3/10910; Table 3). The CHD phenotypes of
the cases with 1q21.1 deletion were transposition of the great
arteries, atrial septal defect and mitral valve dysplasia with ven-
tricular septal defect (Supplementary Material, Table S2).
DISCUSSION
In 948 isolated TOF cases, we found strong association
between duplication at chromosome 1q21.1 and disease risk.
We found no association between 1q21.1 deletion and TOF
risk. In contrast, among 1488 cases of other isolated CHD phe-
notypes, we detected association between deletion, rather than
duplication, at 1q21.1 and disease risk. Our findings therefore
indicate associations between duplication or deletion at this
region and CHD that are to a degree specific for particular
CHD phenotypes, a novel observation. Furthermore, in the
present study, we detected overlapping rare duplication
variants of 100–200 kb in size within the critical region of
Figure 1. The 1q21.1 region (adaptation from the UCSC hg18 Genome Browser) and the summary of findings in TOF and non-TOF mixed CHD cohort. (A) The
region of 1q21.1 is complex (143.5–147.5 Mb is shown) due to the presence of extensive segmental duplication blocks and the existing gaps in the reference
human genome sequence (NCBI Build 36.1). The largest pair of segmental duplications with .99% homology that mediates most of the rearrangements in this
locus is indicated by large orange arrows. (B) RefSeq genes in the region. The critical region is indicated by translucent gray block. (C) The coverage of the
Illumina 660W-Quad (the main platform used in this study) and the location of the custom-designed MLPA probes used in this study are shown. (D) Overview of
1q21.1 duplications (blue bars) and deletions (red bars) identified in our study. The cardiac phenotype is shown after the patient identifier. TGA, transposition of
the great arteries; MV, mitral valve dysplasia with ventricular septal defect; ASD, atrial septal defect.
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1q21.1 that are also enriched (P ¼ 0.01) in our TOF cohort.
These small duplication variants encompass only a single
gene in common, i.e. GJA5, thus indentifying GJA5 as a
critical CHD gene in this locus.
Chromosome 1q21.1 deletion was first proposed as a cause
for CHD by Christiansen et al. (11), who found deletions that
span the entire critical region of 1q21.1 in one syndromic and
two non-syndromic CHD cases among 505 patients referred
for clinical genetic evaluation of suspected DiGeorge or Wil-
liams’ syndrome. All three of the deletion carrying probands
had obstruction of the aortic arch as part of their phenotype.
However, the specificity of that phenotypic association was
likely to have been heavily influenced by selection bias,
since aortic arch interruption and supravalvular aortic stenosis
are classic cardiovascular manifestations of DiGeorge and
Williams’ syndromes, respectively. More recently, deletion
of 1q21.1 was shown to be present more frequently in patients
with variable phenotypes, who had been referred to diagnostic
centres principally for mental retardation accompanied by
other features, than in controls (n ¼ 25/5218 patients; 0/4737
controls; P ¼ 1.1 × 1027) (9). Twelve of the 25 deletion car-
riers had CHD as a feature. A second study of 16 557 patients
referred to a clinical cytogenetics laboratory who were exam-
ined by array comparative genomic hybridization for a range
of abnormalities revealed 21 probands with microdeletion
and 15 with microduplication. However, only 1 of these 36
patients had CHD without other strong environmental predis-
posing factors, a patient with a duplication who had a complex
heart defect (10). No previous study has estimated the fre-
quency of 1q21.1 rearrangements in patients with mixed
CHD phenotypes ascertained on the basis of their heart
disease, rather than on the basis of suspected syndromic fea-
tures; our results demonstrate a modest excess of 1q21.1 dele-
tion in such patients, and no evidence of association with
1q21.1 duplication. In the case of sporadic, isolated TOF,
Greenway et al. (13) found four 1q21.1 duplications and one
1q21.1 deletion in 512 cases and no occurrence in 2265 con-
trols (P ¼ 0.007 and P ¼ 0.18 for 1q21.1 duplication and de-
letion, respectively). Our results confirm that CNV at 1q21.1 is
strongly associated with isolated TOF, and in a cohort almost
twice as large as that investigated by Greenway et al. (13), we
demonstrate that duplication is much more strongly associated
with TOF than is deletion, for which we found no evidence of
association. Interestingly, specificity of 1q21.1 copy number
imbalances has been previously described in other associated
phenotypes: 1q21.1 duplications but not deletions have been
found to be associated with macrocephaly and autism spec-
trum disorders, while 1q21.1 deletions but not duplications
were found to be associated with microcephaly and schizo-
phrenia (10,22).
Table 2. Summary of 1q21.1 CNVs in 2436 CHD patients
Chr Start Length (kb) CN Patient ID parental DNA
availability
Inheri-tance Pheno-type Illumina660 Affy 6.0 MLPA
QS PC
1 144106312 1742 3 CHA-937.1 – n/a TOF Y Y n/a Y
1 144943150 1350 3 GOCHD-982.1 – n/a TOF Y Y n/a Y
1 144943150 1350 3 NOTT-107.1 P+M inh-m TOF Y Y n/a Y
1 144943150 1350 3 CHA-102.1 – n/a TOF Y Y n/a Y
1 144967972 1325 3 CHA-137.1 P+M dn TOF Y Y Y Y
1 144967972 1325 3 CHA-363.1 P+M inh-m TOF Y Y n/a Y
1 144967972a 1321 3 CHA-574.1 M inh-m TOF n/a n/a n/a Y
1 144967972 880 3 CHA-867.1 M n/a TOF/PA Y Y n/a Y
1 145594226 254 3 LEU-30.1 P+M inh-m TOF Y Y n/a Y
1 145594226 254 3 LEU-98.1 – n/a TOF Y Y n/a Y
1 145658466 118 3 CHA-620.1 P+M inh-m TOF Y Y Y Y
1 145658465 118 4 NOTT-319.1 – n/a PA Y Y n/a Y
1 144967972 1419 1 SYD-1499.1 – n/a TGA Y Y n/a Y
1 144967972 1325 1 FCH-397.1 – n/a ASD Y Y n/a Y
1 144967972 1325 1 NOTT-674.1 – n/a MV/VSD Y Y n/a Y
Chr, chromosome; CN, copy number; QS, QuantiSNP; PC, PennCNV; Affy, Affymetrix; Y, yes; n/a, not available; dn, de novo; inh-m, inherited from the mother;
P, paternal; M, maternal; PA, pulmonary atresia; ASD, atrial septal defect; MV/VSD, mitral valve dysplasia with ventricular septal defect; TGA, transposition of
the great arteries.
aThe proband was typed on the Illumina 660W array but failed SNP QC (low call rate) and thus excluded from the array analyses. However, the mother of the
proband was also typed on the Illumina 660W array and passed QC. DNAs from both the proband and mother were analyzed with MLPA, which showed full
1q21.1 duplications with the same breakpoints. This also confirmed the array data from the mother, which passed QC. Thus, the coordinates listed here were
inferred from the mother who transmitted the duplication to the respective proband.
Table 3. Phenotypic specificity of 1q21.1 rearrangements in isolated CHD
Patient cohort 1q21.1 microduplications 1q21.1 microdeletions
n P-value OR (95%CI) n P-value OR (95%CI)
TOF (n ¼ 948) 8 2.2 × 1027 30.9 (10.2–119.0) 0 NS –
Non-TOF (n ¼ 1488) 0 NS – 3 0.04 5.5 (1.4–22.0)
NS, not significant.
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It has been speculated that the 1q21.1 region harbours a
single causal gene critical for both cardiovascular and brain
development that accounts for both aspects of the rearrange-
ment phenotype, but previous studies had not been able to
establish this (9,13). In our TOF cohort, we identified rare
smaller duplications within the critical region of 1q21.1, all
of which encompass GJA5, the strongest candidate gene for
the CHD phenotype in this locus. These overlapping small
GJA5 duplications are rare (3/948) in comparison to the
NAHR-mediated duplications (9/948) found in TOF cases,
but we also found them to be significantly enriched in TOF
when compared with controls (P ¼ 0.01). With the exception
of one patient with PA (a cardiac outflow defect like TOF)
who has a GJA5 triplication, we found no such variant in
our non-TOF CHD cohort. Our results therefore suggest dupli-
cation of GJA5 as the most likely mechanism responsible for
the association of NAHR-mediated duplication at 1q21.1 and
TOF risk. It is not possible to infer directly from our data
that GJA5 deletion is responsible for the association of
NAHR-mediated deletion at 1q21.1 and the risk of other
forms of isolated CHD, although this seems likely.
GJA5 encodes the cardiac gap junction protein connexin-40,
which has key functions in cell adhesion and cell–cell com-
munication. Mice with genetically engineered deletion of
Gja5 have a variety of complex congenital cardiac malforma-
tions, in particular of the cardiac outflow tract (14). There are
as yet no data from animal models of Gja5 overexpression,
although such data would be of evident interest. However,
mice overexpressing Gja1 (Cx43), another connexin isotype,
have outflow tract defects (23,24). While the original report
of the Gja5 knockout mouse suggested that Gja5 was not
expressed in neural crest cells in the mouse, more recent
work has disputed this finding (14,25). The second heart
field plays a critical role in the development of the cardiac
outflow tract, and mutations in genes expressed in the
second heart field result in outflow tract defects both in
mouse models and in humans. Gja5 was recently shown to
be expressed in cells derived from the second heart field
during outflow tract development, where it is regulated by
the key cardiac transcription factor Hand2 (25). TOF patients
are highly prone to atrial and ventricular arrhythmias in later
life which represent a significant source of morbidity and mor-
tality. A number of lines of evidence implicate dysregulation
of GJA5 in atrial arrhythmogenesis (26–29). It would be of
interest to determine whether there is differential susceptibility
to atrial arrhythmia in TOF patients with and without
duplication at 1q21.1 involving GJA5.
Our data do not exclude the possibility that other genes in
the 1q21.1 region also contribute to CHD risk. Among the
possible other candidate genes, CHD1L has been shown to
be overexpressed in patients with TOF, double-outlet right
ventricle and infundibular pulmonary stenosis compared with
controls (30). PRKAB2, which encodes the b2 subunit of
adenosine monophosphate-activated protein kinase, is highly
Figure 2. Small duplications encompassing GJA5 within the critical region of 1q21.1. Five CNVs were identified within the critical region of 1q21.1 in 948 TOF
and 1488 non-TOF CHD cases. Rare duplications of 100–200 kb in size (shown as blue bars) were found in 3/948 TOF cases encompassing a single gene in
common: GJA5. Probands LEU-30 and LEU-98 were found to be distantly related, with estimated genome-wide IBD sharing probabilities for sharing (0,1,2)
alleles IBD to be (0.8581, 0.1369, 0.0050). However, their estimated IBD-sharing probabilities within the 3 Mb region surrounding GJA5 are considerably higher
(0, 0.64, 0.36), and both of them carry duplications with identical breakpoints. Thus, these two observations are likely to represent one ancestral duplication
event. Appropriate correction for the distant relatedness of these two individuals was made in the statistical analyses (see Supplementary Material). In 1488
non-TOF CHD cases, a triplication variant (blue bar) encompassing GJA5 was found in one patient with PA and one deletion variant (red bar) encompassing
the last exon of a non-coding LOC100289211 gene was found in one patient with transposition of the great arteries (TGA). RefSeq genes in the region, the
coverage for the Illumina660W platform and location of the MLPA probes are indicated in the hg18 UCSC Genome Browser (http:// genome.ucsc.edu).
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expressed in the right ventricular outflow tract; mutations in
PRKAG2, a g2 subunit of the same protein, have been found
to cause some familial forms of hypertrophic cardiomyopathy
(31). However, among a total of 2436 CHD cases, we did not
find any smaller CNVs within the 1q21.1 region that impli-
cated any gene other than GJA5, suggesting that any contribu-
tion of such CNVs to CHD risk, while not excluded by our
findings, is of small magnitude. Although our findings at
GJA5 are statistically significant (P ¼ 0.01), do not require
correction for multiple comparisons and are highly biological-
ly plausible, replication of this result in a similarly large and
ethnically homogeneous population of TOF patients will be
of importance in due course.
As in previous studies, we observed marked variable pene-
trance of 1q21.1 CNVs. The reasons for this observation
remain uncertain. A double-hit model has been previously pro-
posed to explain this variable expressivity (32). However, our
power to robustly identify such ‘second hits’ in the small
numbers of cases (n ¼ 15) carrying 1q21.1 CNVs in this
study is low. Additionally, in all five TOF cases where we
observed that the duplication was transmitted from an
unaffected parent, transmission was maternal (P ¼ 0.06).
Although this finding is not significant, it is possible to specu-
late that parent of origin effects could conceivably in part
explain the marked variability in penetrance of cardiac
defects with rearrangements in 1q21 that has been observed
in several previous studies. A larger study comparing the
phenotype when the duplication is paternally or maternally
transmitted would be required to address this.
In summary, our study has defined the relationships between
1q21.1 duplication and isolated TOF, and between the recipro-
cal 1q21.1 deletion and other forms of CHD. Duplication
confers an OR for TOF of 31, and accounts for 1% of the
PAR of TOF, whereas deletion confers an OR and PAR for
non-TOF CHD of 6 and 0.2%, respectively. Within the
1q21.1 region, we showed that duplication of GJA5 alone is
associated with an 10-fold increase in the risk of TOF, iden-
tifying GJA5 as a critical gene for human heart malformation.
MATERIALS AND METHODS
Study subjects and sample collections
Ethical approval was obtained from the local institutional
review boards at each of the participating centres. Informed
consent was obtained from all participants (or from a parent/
guardian, if the patient was a child too young to themselves
consent). Individuals with TOF of Caucasian ancestry together
with their parents (when available) were recruited from mul-
tiple centres in Newcastle, Leeds, Bristol, Liverpool, Oxford,
Nottingham, Leicester (all UK), Leuven (Belgium), Erlangen
(Germany) and Sydney (Australia). Individuals with other
forms of CHD of Caucasian ancestry were also recruited in
Newcastle, Oxford, Nottingham, Leicester, Leuven and
Sydney. Patients that exhibited clinical features of syndromic
developmental abnormalities or learning difficulties were
excluded from the study. Both adult and child patients were
recruited. CHD diagnoses and the presence of any associated
phenotypes were obtained from the medical record. Parents
of cases not reporting a diagnosis of CHD did not undergo
echocardiography. All DNAs were further screened for
DiGeorge and Williams abnormalities and those found with
such anomalies were excluded from the study. Control sub-
jects consisted of 856 individuals of Caucasian ancestry free
of reported CHD from a French population cohort and 6000
individuals of Caucasian ancestry free of reported CHD
from the Wellcome Trust Case-Control Consortium 2
(WTCCC2) control cohort (3000 individuals from 1958
British Birth Cohort and 3000 individuals from UK Blood
Service). Controls did not undergo echocardiography. DNAs
from cases were extracted from blood or saliva. DNAs from
the French population cohort and UK Blood Service were
blood-derived and DNAs from 1958 British Birth Cohort
were cell line derived.
Genotyping and quality-control criteria
Genotyping for all CHD probands and the French control
cohort was performed at the Centre National de Ge´notypage
(Evry Cedex, France). Normalized intensity and genotype
data were obtained from the genotyping centre. TOF patients
and family members (907 affected offspring and 747 unaffect-
ed parents), 1987 non-TOF CHD patients and 856 unrelated
individuals from a French control cohort were genotyped on
the Illumina 660W-Quad platform. Additionally, 206 of the
same TOF individuals were also typed on Affymetrix 6.0
arrays. Per sample SNP QC analyses were performed to
exclude any duplicates, individuals with non Caucasian ances-
try and gender mismatches. Samples with low call rate
(,98.8%) and high heterozygosity were excluded. Additional
intensity quality-control parameters were applied to minimize
heterogeneity due to multi-centre variation in DNA source and
treatment. Samples were excluded when they failed the fol-
lowing QC criteria: (i) a standard deviation of autosomal log
R ratio (LRR) values .3.0; (ii) GC wave factor of the LRR
outside the range of 20.1 , X , 0.1 (18); (iii) a standard de-
viation of B allele frequency values .0.15 after GC correction
(19). Following these QC measures, 807 TOF patients and 697
of their family members (8 affected and 689 unaffected), 1488
patients with non-TOF CHD and 841 control individuals from
the French cohort were included in the final analyses. The
phenotype classification summary of non-TOF CHD indivi-
duals can be found in Table 1. WTCCC2 controls were
typed on Affymetrix 6.0 arrays. Further details on genotyping
and QC criteria (n ¼ 5919 passed QC) can be found in a pre-
viously published study (33) (http://www.wtccc.org.uk/ccc2).
CNV calling algorithms and verification criteria
CNV detection on the Illumina 660W platform was performed
using both PennCNV (18) and QuantiSNP (19) CNV-calling
algorithms. CNV detection on the Affymetrix 6.0 platform
was performed using the Birdseye algorithm from the Bird-
suite (34) package. The number of markers used to call
CNV within the 1 Mb minimal region of NAHR-mediated
events in the 1q21.1 locus on the Illumina 660W and Affyme-
trix 6.0 platforms are 235 and 640, respectively. Within the
minimal region (100 kb) of small duplications that encom-
pass GJA5, 36 and 104 markers were available in the Illumina
660W and Affymetrix 6.0 platforms, respectively. CNV calls
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within the 1q21.1 locus that appeared to be artificially split as
the result of coverage gaps on the SNP platforms were exam-
ined manually and joined (see Supplementary Material,
Fig. S1 and S2). All CNV calls with Bayes factor .50 were
confirmed with MLPA and Affymetrix 6.0 array (19). CNV
coordinates were based on NCBI build 36.1 (hg18).
MLPA design, assay and analysis
We performed MLPA analyses of the critical region of 1q21.1
in 574 TOF probands (433 of which were also typed on the
Affymetrix 6.0 and/or Illumina 660W arrays) and 433
non-TOF CHD probands (all were also typed on the Illumina
660W arrays). MLPA probes were designed with MAPD (35)
software, using the default settings. The resulting list of candi-
date probes was subjected to BLAT (36) search in order to
ensure specificity and to obtain genomic positions. Candidate
probes that overlapped known SNPs (37) and/or segmental
duplications (38) [identified by using UCSC Extended DNA
utility (39,40)] were excluded. The remaining candidate
probes with the highest score given by the MAPD software
that met all the MRC Holland guidelines (http://www.
mrc-holland.com) were chosen for synthesis. Twenty probes
(ranging from 100–140 bp final product size) that targeted
GJA5 (10), CHD1L (2), ACP6 (2), GJA8 (2), PRKAB2 (2),
TXNIP (1) and ANKRD34A (1) were synthesized. Nine 1q21
probes were used for each MLPA assay in addition to two
control synthetic probes targeting copy number neutral
regions. All probe sequences are available upon request.
All MLPA (41) assays were performed with reagents from
the MRC Holland P200 kit (Amsterdam, the Netherlands)
and custom design synthetic oligonucleotide probes (Integrated
DNA Technology, IA, USA). Genomic DNA (100 ng in 5 ml
TE) was denatured for 30 min at 958C and cooled down to
258C before addition of 35 fmoles of synthetic custom design
probes, 1 ml of P200 probe mix and 1.5 ml of MLPA buffer.
This was followed by hybridization at 608C for 16 h. Hybri-
dized probes were ligated with 1 U of Ligase-65 for 15 min
at 548C, followed by ligase deactivation for 5 min at 988C.
Afterwards, 5 ml of the ligated products were added to 15 ml
of polymerase chain reaction (PCR) buffer 2:13 dilution in
H2O at 48C, and the temperature was raised to 608C before
the remaining PCR reagents (2.5 nmoles of dNTPs, 10 pmol
fluorescein amidite-labelled universal primers and 2.5 U of
SALSA polymerase) were added to make the final reaction
volume to 25 ml. PCR reaction was carried out in 33 cycles
(958C for 30 s, 608C for 30 s and 728C for 1 min), followed
by a final extension at 728C for 20 min. The final MLPA
products were subsequently resolved on ABI 3730xl
(Applied Biosystems, CA, USA), using the MRC Holland
protocol (http://www.mrc-holland.com). The data were
analyzed with the GeneMarker v.1.85 software (SoftGenetics,
PA, USA), in which population normalization was applied, and
the peak areas were used to calculate relative dosage.
Incorporation of control data from previously
published studies
In addition to 841 control individuals from the French cohort
and 5919 WTCCC2 controls, we examined the frequency of
1q21.1 rearrangements in 4150 control individuals from previ-
ously published studies (8,20,21) that used high-density SNP
platforms comparable to the platforms used in this study
(with coverage of .200 probes in the critical region of
1q21.1). For details, see Supplementary Material, Table S1.
Statistical analysis
Two-sided Fisher’s exact tests were used to compare the fre-
quency of NAHR-mediated 1q21.1 duplications/deletions.
Stata 11 was used to compute P-values, OR and 95% CI by
Cornfield approximation. The frequency of small GJA5 dupli-
cations was compared by maximum likelihood estimation
using two binomial distributions (details can be found in Sup-
plementary Material). PAR was calculated using the formula:
100(P(OR21))/(1+(P(OR21))), in which P is the proportion
of control population with the 1q21.1 duplication/deletion.
Genomewide identity-by-descent (IBD) sharing was calcu-
lated using 41692 autosomal SNPs in PLINK (42). IBD
sharing for the 1q21.1 locus was calculated using 268 SNPs
in a roughly 3 Mb region around GJA5.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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